Multiple Myeloma Presentations
(Company-Sponsored)

Selinexor

Selinexor in combination with pomalidomide and dexamethasone (SPd) for treatment of patients with relapsed refractory multiple myeloma (RRMM).

Christine Chen, Princess Margaret Cancer Centre
726
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis
Monday, December 7, 2020, 1:30 p.m. to 3:00 p.m. ET
Channel 10 (Virtual Meeting)

Selinexor in combination with carfilzomib and dexamethasone, all once weekly (SKd), for patients with relapsed/refractory multiple myeloma

Cristina Gasparetto, Duke University Medical Center
1366
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Date and Time: Saturday, December 5, 2020, 7:00 a.m. to 3:30 p.m. ET
Location: Poster Hall (Virtual Meeting)

Selinexor, lenalidomide and dexamethasone (SRd) for patients with relapsed/refractory and newly diagnosed multiple myeloma

Darrell White, Dalhousie University
1393
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Saturday, December 5, 2020, 7:00 a.m. to 3:30 p.m. ET
Location: Poster Hall (Virtual Meeting)

Effect of prior treatment with proteasome inhibitors on the efficacy and safety of once-weekly selinexor, bortezomib, and dexamethasone in comparison with twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis from the BOSTON study

Maria Mateos, University Hospital of Salamanca
2297
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
Sunday, December 6, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Impact of prior therapies on the safety and efficacy of once-weekly selinexor, bortezomib, and dexamethasone compared with twice-weekly bortezomib and dexamethasone in relapsed ore refractory multiple myeloma: results from the BOSTON study

Maria Mateos, University Hospital of Salamanca
3245
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
Monday, December 7, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Once weekly selinexor, bortezomib, and dexamethasone versus twice weekly bortezomib and dexamethasone in relapsed ore refractory multiple myeloma: age and frailty subgroup analyses from the phase 3 BOSTON study

Harold Auner, Imperial College London
3215
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
Saturday, December 5, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Once weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high-risk cytogenetic risk planned subgroup analyses from the phase 3 BOSTON study

Shambavi Richard, Mount Sinai Hospital
3489
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Monday, December 7, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Lymphoma Presentations (Company-Sponsored)

Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a post-hoc analysis from the SADAL pivotal study

Marie Maerevoet, Institut Jules Bordet
626
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Saturday, December 5, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Selinexor efficacy and safety are independent of renal function in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a post-hoc analysis from the pivotal phase 2b SADAL study

Jason Westin, The University of Texas MD Anderson Cancer Center
1384
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Saturday, December 5, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

A six-protein activity signature defines favorable response to selinexor treatment for patients with diffuse large B-cell lymphoma (DLBCL)

Christopher Walker, Karyopharm Therapeutics
2125
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II
Sunday, December 6, 2020, 7:00 a.m. to 3:30 p.m. ET
Poster Hall (Virtual Meeting)

Click here for all of the selinexor abstracts on the ASH online library (including investigator-sponsored presentations)

L